RecruitingNot ApplicableNCT07276243

Polidocanol Foam With or Without Transdermal Laser in Varicose Veins

Comparação da eficácia clínica e estética Entre o Tratamento de Varizes Com Espuma de Polidocanol Associada ou não ao Laser transdérmico: Ensaio clínico Randomizado


Sponsor

Hospital Universitario Pedro Ernesto

Enrollment

102 participants

Start Date

Mar 24, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This randomized, parallel clinical trial with blinded outcome assessment will compare the clinical and aesthetic outcomes of polidocanol foam sclerotherapy alone versus polidocanol foam associated with long-pulse 1064 nm Nd:YAG transdermal laser in the treatment of lower-limb tributary varicose veins. The primary endpoint is venous occlusion rate at 30 days, assessed by Doppler ultrasound. Secondary outcomes include cutaneous hyperpigmentation, pain, patient satisfaction, and adverse events.


Eligibility

Min Age: 21 YearsMax Age: 75 Years

Inclusion Criteria8

  • Age 21 to 75 years
  • CEAP clinical class 1-3
  • Lower limb tributary varicose veins 2,5 to 4,0 mm in diameter on Doppler ultrasound.
  • Vein depth up to 4 mm from the skin surface.
  • Tributary vein may originate from the great or small saphenous vein as long as the saphenous vein is competent on Doppler.
  • Reflux limited to the target tributary.
  • Body mass index (BMI) < 35 km²/m²
  • Able and willing to provide informed consent.

Exclusion Criteria13

  • CEAP clinical class ≥ 4
  • Axial reflux of the great or small saphenous vein requiring prior treatment
  • Tributary vein diameter < 2.5 mm or > 4.0 mm on Doppler
  • Tributary vein depth > 4 mm from the skin surface
  • Pregnancy or breastfeeding
  • Known allergy or hypersensitivity to polidocanol
  • History of deep vein thrombosis or pulmonary embolism in the last 6 months
  • Use of anticoagulant therapy that cannot be safely interrupted
  • Active skin infection or ulcer at the treatment site
  • Autoimmune or connective tissue disease with active vasculitis
  • BMI ≥ 35 kg/m²
  • Inability to comply with follow-up visits
  • Previous treatment of the target vein in the past 6 months (laser, foam, surgery, or microphlebectomy).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPolidocanol foam sclerotherapy

Polidocanol foam prepared using the Tessari method. Concentration 0,5% (Foam Arm) or 0,25% (Foam + Laser Arm), injected under ultrasound guidance.

DEVICETransdermal Nd:YAG 1064 nm laser

Long-pulse Nd:YAG 1064 nm transdermal laser applied along the treated vein path immediately after foam injection.


Locations(1)

Hospital Universitário Pedro Ernesto - UERJ

Rio de Janeiro, Rio de Janeiro, Brazil

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07276243


Related Trials